MaxCyte (LON:MXCT) Stock Falls 5.8% – Time to Sell?

MaxCyte, Inc. (LON:MXCT)’s share price was down 5.8% on Monday. The company traded as low as GBX 1.29 and last traded at GBX 1.31. 873,653 shares traded hands during mid-day trading, an increase of 1,977% from the average daily volume of 42,065 shares. The stock had previously closed at GBX 1.39.

MaxCyte Stock Up 3.2%

The company has a current ratio of 10.88, a quick ratio of 14.38 and a debt-to-equity ratio of 8.74. The firm’s 50 day simple moving average is GBX 1.26 and its 200-day simple moving average is GBX 1.07. The stock has a market capitalization of £1.38 million, a price-to-earnings ratio of -0.03 and a beta of 1.13.

About MaxCyte

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.